Compare Regeneron Pharmaceuticals Inc (REGN) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Smith & Nephew plc — how do they compare? Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 6.9× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Smith & Nephew plc for 121 Days on average.
| REGN | SNN | |
|---|---|---|
Market Cap | $76.14B | $11.10B |
Volume | 500,239 | 1,051,703 |
Sector | Health | Health |
52-Week High | $852.03 | $37.17 |
52-Week Low | $557.73 | $26.42 |
Typical Hold Time | 107 Days | 121 Days |
Enterprise Value | $70.85B | $14.13B |
Dividend Yield | 0.51% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, down 0.34% with a bearish technical signal. The company maintains strong fundamentals with a 27.86% net income margin and consistent earnings beats. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront payments and milestone potential. Cash flow improved significantly in 2025 with $635 million net cash flow versus negative flows in prior years.
The stock presents a compelling investment case with strong profitability, positive analyst sentiment (69% buy ratings), and a $849.84 consensus price target offering 15% upside. Key risks include competitive pressures in ophthalmology drugs and reliance on key partnerships. The expanded Sanofi collaboration and promising clinical pipeline provide catalysts for growth.
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
